A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM‐STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma. Here, CKM is linked to intrahepatic cholangiocarcinoma.